876922-98-4Relevant academic research and scientific papers
Design and synthesis of novel tricyclic benzoxazines as potent 5-HT 1A/B/D receptor antagonists leading to the discovery of 6-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-4 h-imidazo[5,1-c][1,4] benzoxazine-3-carboxamide (GSK588045)
Bromidge, Steven M.,Arban, Roberto,Bertani, Barbara,Bison, Silvia,Borriello, Manuela,Cavanni, Paolo,Dal Forno, Giovanna,Di-Fabio, Romano,Donati, Daniele,Fontana, Stefano,Gianotti, Massimo,Gordon, Laurie J.,Granci, Enrica,Leslie, Colin P.,Moccia, Luca,Pasquarello, Alessandra,Sartori, Ilaria,Sava, Anna,Watson, Jeannette M.,Worby, Angela,Zonzini, Laura,Zucchelli, Valeria
experimental part, p. 5827 - 5843 (2010/11/04)
Bioisoteric replacement of the metabolically labile N-methyl amide group of a series of benzoxazinones with small heterocyclic rings has led to novel series of fused tricyclic benzoxazines which are potent 5-HT1A/B/D receptor antagonists with a
Development of an efficient large-scale synthesis for a 4 H-imidazo[5,1- c ][1,4]benzoxazine-3-carboxamide derivative for depression and anxiety
Giubellina, Nicola,Stabile, Paolo,Laval, Gilles,Perboni, Alcide D.,Cimarosti, Zadeo,Westerduin, Pieter,Cooke, Jason W. B.
experimental part, p. 859 - 867 (2011/03/20)
The development and scale-up of an optimized synthesis for a novel drug candidate for depression and anxiety is presented. The updated synthesis represents a convergent and efficient four-stage approach to the API, overcoming high cost of goods (COG), gen
FUSED TRICYCLIC DERIVATIVES FOR THE TREATMENT OF PSYCHOTIC DISORDERS
-
Page/Page column 122, (2010/10/20)
Compounds of formula (I) wherein R1, R2, X, A, Y, B, Z1, Q, p, r and s are defined in the specification for treating inter alia psychotic disorders, depressive disorders, anxiety disorders and sexual dysfunctions.
